{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:03:38Z","timestamp":1794243818334,"version":"4.9.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ordos Health Commission Key discipline Project"},{"name":"Inner Mongolia Medical University Science and Technology million Project funding"},{"DOI":"10.13039\/501100004763","name":"Inner Mongolia natural science foundation","doi-asserted-by":"crossref","award":["2021MS08133"],"award-info":[{"award-number":["2021MS08133"]}],"id":[{"id":"10.13039\/501100004763","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004763","name":"Inner Mongolia natural science foundation","doi-asserted-by":"crossref","award":["2021MS08133"],"award-info":[{"award-number":["2021MS08133"]}],"id":[{"id":"10.13039\/501100004763","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004763","name":"Inner Mongolia natural science foundation","doi-asserted-by":"crossref","award":["2021MS08133"],"award-info":[{"award-number":["2021MS08133"]}],"id":[{"id":"10.13039\/501100004763","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004763","name":"Inner Mongolia natural science foundation","doi-asserted-by":"crossref","award":["2021MS08133"],"award-info":[{"award-number":["2021MS08133"]}],"id":[{"id":"10.13039\/501100004763","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004763","name":"Inner Mongolia natural science foundation","doi-asserted-by":"crossref","award":["2021MS08133"],"award-info":[{"award-number":["2021MS08133"]}],"id":[{"id":"10.13039\/501100004763","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004763","name":"Inner Mongolia natural science foundation","doi-asserted-by":"crossref","award":["2021MS08133"],"award-info":[{"award-number":["2021MS08133"]}],"id":[{"id":"10.13039\/501100004763","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004763","name":"Inner Mongolia natural science foundation","doi-asserted-by":"crossref","award":["2021MS08133"],"award-info":[{"award-number":["2021MS08133"]}],"id":[{"id":"10.13039\/501100004763","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Inner Mongolia Autonomous Region Talent Development Fund","award":["202265"],"award-info":[{"award-number":["202265"]}]},{"name":"Inner Mongolia Autonomous Region Talent Development Fund","award":["202265"],"award-info":[{"award-number":["202265"]}]},{"name":"Inner Mongolia Autonomous Region Talent Development Fund","award":["202265"],"award-info":[{"award-number":["202265"]}]},{"name":"Inner Mongolia Autonomous Region Talent Development Fund","award":["202265"],"award-info":[{"award-number":["202265"]}]},{"name":"Inner Mongolia Autonomous Region Talent Development Fund","award":["202265"],"award-info":[{"award-number":["202265"]}]},{"name":"Inner Mongolia Autonomous Region Talent Development Fund","award":["202265"],"award-info":[{"award-number":["202265"]}]},{"name":"Inner Mongolia Autonomous Region Talent Development Fund","award":["202265"],"award-info":[{"award-number":["202265"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>We aim to investigate the correlation between gene polymorphisms and cisplatin chemotherapy-induced nausea and vomiting (CINV), which was prevented by olanzapine or aprepitant triple antiemetic regimen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Before chemotherapy, the blood samples of 89 malignant tumor patients who received multi-day chemotherapy with cisplatin were collected for sequencing and typing. As there were duplicate patients enrolled in different chemotherapy cycles, there were a total of 190 cases. The patients were divided into two groups randomly, who received the triple antiemetic regimen of olanzapine or aprepitant combined with 5-HT3RA and dexamethasone. The main evaluation indicators were the total protection (TP) rate in the acute phase (0\u201324\u00a0h), the delayed phase (25\u2013120\u00a0h) and the overall phase (0-120\u00a0h).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Univariate analysis was performed on genetic loci that reached H-W balance with TP. In the olanzapine group, increased TP in the acute phase was associated with <jats:italic>HTR3A<\/jats:italic> rs1176719 non-GG (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05) genotype etc. Increased TP in the delayed phase was associated with <jats:italic>HTR3A<\/jats:italic> rs1176719 non-GG (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05) genotype etc. In the aprepitant group, increased TP in the acute phase was associated with the <jats:italic>MTHFR<\/jats:italic> rs1801131 TT (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05) genotype etc. Increased TP in the delayed phase was associated with <jats:italic>HTR3A<\/jats:italic> rs1062613 CC (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05) genetype ect. Multivariate Logistic regression analysis showed that <jats:italic>HTR3B<\/jats:italic> rs7943062GG (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05) genotype etc. were correlated with increased TP in the delayed phase. <jats:italic>MTHFR<\/jats:italic> rs1801131TT genotype was associated with increased TP in the acute phase (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05) and delayed phase (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study found that gene polymorphisms, including <jats:italic>HTR3B<\/jats:italic> (rs1062613, rs1176719, rs2276303), <jats:italic>HTR3B<\/jats:italic> (rs45460698, rs7943062), <jats:italic>HTR3C<\/jats:italic> (rs6766410), <jats:italic>ERCC1<\/jats:italic> (rs3212986), <jats:italic>ERCC4<\/jats:italic> (rs744154) and <jats:italic>MTHFR<\/jats:italic>(rs1801131), may be independent prognostic factors for CINV.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12920-023-01719-0","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T13:02:24Z","timestamp":1699016544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A randomized trial evaluating the association between related gene polymorphism and nausea and vomiting induced by cisplatin multi-day chemotherapy"],"prefix":"10.1186","volume":"16","author":[{"given":"Yilan","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaowa","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zewei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanfu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,3]]},"reference":[{"key":"1719_CR1","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2147\/PGPM.S317229","volume":"14","author":"Y Jin","year":"2021","unstructured":"Jin Y, Jin G, Zhao J, et al. Clinical Observation of Gene Polymorphism of Olanzapine or Aprepitant in Prevention of CINV. Pharmgenomics Pers Med. 2021;14:867\u201375. https:\/\/doi.org\/10.2147\/PGPM.S317229. Published 2021 Jul 15.","journal-title":"Pharmgenomics Pers Med"},{"issue":"18 Suppl","key":"1719_CR2","first-page":"398","volume":"24","author":"SA Soefje","year":"2018","unstructured":"Soefje SA. Strategies to improve CINV outcomes in managed care. Am J Manag Care. 2018;24(18 Suppl):398\u2013S404.","journal-title":"Am J Manag Care"},{"key":"1719_CR3","doi-asserted-by":"crossref","unstructured":"Sekine I, Segawa Y, Kubota K et al. Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis[J]. Cancer Sci 2013,104(6):711\u20137.","DOI":"10.1111\/cas.12146"},{"issue":"18 Suppl","key":"1719_CR4","first-page":"391","volume":"24","author":"JJ Natale","year":"2018","unstructured":"Natale JJ. Overview of the prevention and management of CINV. Am J Manag Care. 2018;24(18 Suppl):391\u2013S397.","journal-title":"Am J Manag Care"},{"issue":"28","key":"1719_CR5","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.2174\/138161206778522029","volume":"12","author":"AJ Thompson","year":"2006","unstructured":"Thompson AJ, Lummis SC. 5-HT3 receptors. Curr Pharm Des. 2006;12(28):3615\u201330. https:\/\/doi.org\/10.2174\/138161206778522029.","journal-title":"Curr Pharm Des"},{"issue":"1","key":"1719_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.neuropharm.2008.08.003","volume":"56","author":"NM Barnes","year":"2009","unstructured":"Barnes NM, Hales TG, Lummis SC, Peters JA. The 5-HT3 receptor\u2013the relationship between structure and function. Neuropharmacology. 2009;56(1):273\u201384. https:\/\/doi.org\/10.1016\/j.neuropharm.2008.08.003.","journal-title":"Neuropharmacology"},{"issue":"5","key":"1719_CR7","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2217\/14622416.9.5.501","volume":"9","author":"B Niesler","year":"2008","unstructured":"Niesler B, Kapeller J, Hammer C, Rappold G. Serotonin type 3 receptor genes: HTR3A, B, C, D, E. Pharmacogenomics. 2008;9(5):501\u20134. https:\/\/doi.org\/10.2217\/14622416.9.5.501.","journal-title":"Pharmacogenomics"},{"key":"1719_CR8","doi-asserted-by":"crossref","unstructured":"Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors[J]. Pharmacol Biochem Behav 2002,71(4):533\u201354.","DOI":"10.1016\/S0091-3057(01)00746-8"},{"issue":"1","key":"1719_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/tpj.2010.75","volume":"12","author":"MV Tzvetkov","year":"2012","unstructured":"Tzvetkov MV, Saadatmand AR, Bokelmann K, et al. Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron[J]. Pharmacogenomics J. 2012;12(1):22\u20139.","journal-title":"Pharmacogenomics J"},{"key":"1719_CR10","doi-asserted-by":"crossref","unstructured":"Lee AM, Shi Q, Pavey E et al. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant Colon Cancer Treatment (NCCTG N0147)[J]. JNCI: Journal of the National Cancer Institute,2014,106(12).","DOI":"10.1093\/jnci\/dju298"},{"key":"1719_CR11","unstructured":"Gao Changming L, Jianwei T, Toshiro et al. Research on the relationship between methylenetetrahydrofolate reductase gene polymorphism and sensitivity to gastric cancer chemotherapy [J]. Chin J Epidemiol, 2004(12): 52\u20136."},{"issue":"5","key":"1719_CR12","first-page":"1505","volume":"26","author":"M Yokoi","year":"2018","unstructured":"Yokoi M, Tsuji D, Suzuki K, et al. Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy. Support Care Cancer. 2018;26(5):1505\u201313.","journal-title":"Support Care Cancer"},{"issue":"5","key":"1719_CR13","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/tpj.2016.38","volume":"17","author":"D Tsuji","year":"2017","unstructured":"Tsuji D, Yokoi M, Suzuki K, et al. Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study. Pharmacogenomics J. 2017;17(5):435\u201340.","journal-title":"Pharmacogenomics J"},{"key":"1719_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctro.2016.12.001","volume":"2","author":"D Oliva","year":"2017","unstructured":"Oliva D, Nilsson M, Andersson B, et al. Single nucleotide polymorphisms might influence chemotherapy induced nausea in women with Breast cancer[J]. Clin Translational Radiation Oncol. 2017;2:1\u20136.","journal-title":"Clin Translational Radiation Oncol"},{"key":"1719_CR15","doi-asserted-by":"crossref","unstructured":"Kitamura T, Qian BZ, Soong D et al. CCL2-induced chemokine cascade promotes Breast cancer Metastasis by enhancing retention of metastasis-associated macrophages[J]. J Exp Med 2015,212(7):1043\u201359.","DOI":"10.1084\/jem.20141836"},{"key":"1719_CR16","doi-asserted-by":"crossref","unstructured":"Mukoyama N, Yoshimi A, Goto A et al. An analysis of behavioral and genetic risk factors for Chemotherapy-Induced nausea and vomiting in Japanese Subjects[J]. Biol Pharm Bull 2016,39(11):1852\u20138.","DOI":"10.1248\/bpb.b16-00440"},{"issue":"6","key":"1719_CR17","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.12122\/j.issn.1673-4254.2023.06.18","volume":"43","author":"Q Yang","year":"2023","unstructured":"Yang Q, Liu X, Jiang Y, Ma J, Nan. Fang Yi Ke Da Xue Xue Bao. 2023;43(6):1017\u201322. https:\/\/doi.org\/10.12122\/j.issn.1673-4254.2023.06.18.","journal-title":"Fang Yi Ke Da Xue Xue Bao"},{"issue":"7","key":"1719_CR18","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3736\/jcim20100702","volume":"8","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D, Consort Group. Zhong Xi Yi Jie He Xue Bao. 2010;8(7):604\u201312. https:\/\/doi.org\/10.3736\/jcim20100702.","journal-title":"Zhong Xi Yi Jie He Xue Bao"},{"key":"1719_CR19","doi-asserted-by":"crossref","unstructured":"J. B. McCrea, A. K. Majumdar, M. R. Goldberg et al., \u201cEffects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone,\u201d Clinical Pharmacology & erapeutics, vol. 74, no. 1, pp. 17\u201324, 2003.","DOI":"10.1016\/S0009-9236(03)00066-3"},{"issue":"6","key":"1719_CR20","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1097\/00008571-200108000-00002","volume":"11","author":"B Niesler","year":"2001","unstructured":"Niesler B, Flohr T, N\u00f6then MM, et al. Association between the 5\u2019 UTR variant C178T of the serotonin receptor gene HTR3A and bipolar affective disorder. Pharmacogenetics. 2001;11(6):471\u20135. https:\/\/doi.org\/10.1097\/00008571-200108000-00002.","journal-title":"Pharmacogenetics"},{"issue":"5","key":"1719_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00008571-200405000-00001","volume":"14","author":"R Kaiser","year":"2004","unstructured":"Kaiser R, Tremblay PB, Sezer O, Possinger K, Roots I, Brockm\u00f6ller J. Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists. Pharmacogenetics. 2004;14(5):271\u20138. https:\/\/doi.org\/10.1097\/00008571-200405000-00001.","journal-title":"Pharmacogenetics"},{"key":"1719_CR22","doi-asserted-by":"publisher","unstructured":"Lehmann AS, Renbarger JL, McCormick CL, Topletz AR, Rouse C, Haas DM. Pharmacogenetic predictors of nausea and vomiting of pregnancy severity and response to antiemetic therapy: a pilot study. BMC Pregnancy Childbirth. 2013;13:132. Published 2013 Jun 20. https:\/\/doi.org\/10.1186\/1471-2393-13-132.","DOI":"10.1186\/1471-2393-13-132"},{"issue":"19","key":"1719_CR23","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1093\/hmg\/ddn195","volume":"17","author":"J Kapeller","year":"2008","unstructured":"Kapeller J, Houghton LA, M\u00f6nnikes H, et al. First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. Hum Mol Genet. 2008;17(19):2967\u201377. https:\/\/doi.org\/10.1093\/hmg\/ddn195.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"1719_CR24","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1073\/pnas.0708454105","volume":"105","author":"K Krzywkowski","year":"2008","unstructured":"Krzywkowski K, Davies PA, Feinberg-Zadek PL, Br\u00e4uner-Osborne H, Jensen AA. High-frequency HTR3B variant associated with major depression dramatically augments the signaling of the human 5-HT3AB receptor. Proc Natl Acad Sci U S A. 2008;105(2):722\u20137. https:\/\/doi.org\/10.1073\/pnas.0708454105.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"1719_CR25","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1200\/JCO.2003.05.164","volume":"21","author":"PB Tremblay","year":"2003","unstructured":"Tremblay PB, Kaiser R, Sezer O, et al. Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol. 2003;21(11):2147\u201355. https:\/\/doi.org\/10.1200\/JCO.2003.05.164.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1719_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/ajco.12575","volume":"13","author":"G Kang","year":"2017","unstructured":"Kang G, Kim KR, Shim HJ, et al. Effect of the allelic variants of ABCB1, CYP2D6 and HTR3B on response of ramosetron to prevent chemotherapy-induced nausea and vomiting in Korean cancer patients. Asia Pac J Clin Oncol. 2017;13(1):53\u201360. https:\/\/doi.org\/10.1111\/ajco.12575.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"10","key":"1719_CR27","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1093\/jjco\/hyr117","volume":"41","author":"DA Perwitasari","year":"2011","unstructured":"Perwitasari DA, Wessels JA, van der Straaten RJ, et al. Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy. Jpn J Clin Oncol. 2011;41(10):1168\u201376. https:\/\/doi.org\/10.1093\/jjco\/hyr117.","journal-title":"Jpn J Clin Oncol"},{"key":"1719_CR28","doi-asserted-by":"publisher","unstructured":"De Rienzo F, Del Cadia M, Menziani MC. A first step towards the understanding of the 5-HT3 receptor subunit heterogeneity from a computational point of view. Phys Chem Chem Phys. 2012;14(36):12625\u201312636. https:\/\/doi.org\/10.1039\/c2cp41028a.","DOI":"10.1039\/c2cp41028a"},{"issue":"10","key":"1719_CR29","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00432-008-0387-1","volume":"134","author":"PA Fasching","year":"2008","unstructured":"Fasching PA, Kollmannsberger B, Strissel PL, et al. Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. J Cancer Res Clin Oncol. 2008;134(10):1079\u201386. https:\/\/doi.org\/10.1007\/s00432-008-0387-1.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"1719_CR30","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10549-014-2832-y","volume":"144","author":"D Pud","year":"2014","unstructured":"Pud D, Har-Zahav G, Laitman Y, et al. Association between variants of 5-hydroxytryptamine receptor 3\u00a0C (HTR3C) and chemotherapy-induced symptoms in women receiving adjuvant treatment for Breast cancer. Breast Cancer Res Treat. 2014;144(1):123\u201331. https:\/\/doi.org\/10.1007\/s10549-014-2832-y.","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"1719_CR31","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2217\/14622416.9.8.1027","volume":"9","author":"MB Ward","year":"2008","unstructured":"Ward MB, Kotasek D, McKinnon RA. Investigation of HTR3C mutations for association with 5HT(3) receptor antagonist anti-emetic efficacy. Pharmacogenomics. 2008;9(8):1027\u201333. https:\/\/doi.org\/10.2217\/14622416.9.8.1027.","journal-title":"Pharmacogenomics"},{"issue":"12","key":"1719_CR32","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.2217\/pgs.14.107","volume":"15","author":"JK Lamba","year":"2014","unstructured":"Lamba JK, Fridley BL, Ghosh TM, Yu Q, Mehta G, Gupta P. Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell Lung cancer. Pharmacogenomics. 2014;15(12):1565\u201374. https:\/\/doi.org\/10.2217\/pgs.14.107.","journal-title":"Pharmacogenomics"},{"issue":"1","key":"1719_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/tpj.2011.38","volume":"13","author":"HE Wheeler","year":"2013","unstructured":"Wheeler HE, Gamazon ER, Stark AL, et al. Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J. 2013;13(1):35\u201343. https:\/\/doi.org\/10.1038\/tpj.2011.38.","journal-title":"Pharmacogenomics J"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-023-01719-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-023-01719-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-023-01719-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T13:06:32Z","timestamp":1699016792000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-023-01719-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,3]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1719"],"URL":"https:\/\/doi.org\/10.1186\/s12920-023-01719-0","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,3]]},"assertion":[{"value":"17 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approval by the Ethics Committee of Ordos Central Hospital (2020-006). Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"276"}}